Latest RedHill Biopharma News & Updates

See the latest news and media coverage for RedHill. We track all announcements, press releases, and industry mentions in real time, all in one place.

RedHill Biopharma (RedHill)

Specialty pharmaceutical company developing and commercializing therapies

redhillbio.com

Headquarters: Raleigh, United States
Founded year: 2009
Company type: Public company
Number of employees: 51–200
Industry: Pharmaceuticals

Last updated October 19

Latest news about RedHill Biopharma (RedHill)

In short: RedHill acquired Rebyota and Clenpiq rights, divested Talicia, and advanced opaganib and RHB-102 programs.

Company announcements

October 19 RedHill

RedHill Biopharma wins NIH grant for opaganib research

The $2.9 million grant supports clinical development of RedHill's opaganib combined with CAR T-cells to treat ultra-high-risk multiple myeloma.

September 30 RedHill

RedHill reports first half 2026 financial results

The company acquired Rebyota and Clenpiq rights via Talicia divestment.

September 1 RedHill

RedHill secures exclusive commercialization rights to two Ferring gastrointestinal drugs

The $12 million upfront deal includes royalties and milestones. Combined 2025 net sales for Rebyota and Clenpiq reached approximately $37.5 million.

August 31 RedHill

RedHill divests Talicia to Apotex for an upfront payment of eighteen million dollars plus milestones

The transaction secures immediate capital and future milestone payments to fund strategic growth opportunities and accelerate operational profitability.

Media coverage

September 30 WFMZ

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results | PR Newswire | wfmz.com

TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today...

September 17 BioBuzz

RedHill Biopharma Buys Global Rights to Two Established GI Drugs from Ferring

RedHill Biopharma Ltd., the specialty biopharmaceutical company with a U.S. commercial office in Raleigh, North Carolina, announced on September 1, 2026...

September 10 Yahoo Finance

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

RedHill Biopharma Ltd. (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq from Ferring Pharmaceuticals. The agreement has an...

September 1 The Pharma Letter

RedHill acquires rights to Ferring's Rebyota and Clenpiq

RedHill Biopharma today announced the transformational acquisition of exclusive global and US commercialization rights to Rebyota (fecal microbiota, live-jslm). and Clenpiq (a combination of sodium...

Never miss news about RedHill

Track RedHill and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

RedHill competitors & trending companies

Browse news for competitors to RedHill and other trending companies.